These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 28766213)
1. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk. O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213 [TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing. Chang J; Seng S; Yoo J; Equivel P; Lum SS Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386 [TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
5. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696 [TBL] [Abstract][Full Text] [Related]
6. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627 [TBL] [Abstract][Full Text] [Related]
7. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Piccinin C; Panchal S; Watkins N; Kim RH Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018 [No Abstract] [Full Text] [Related]
8. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395 [TBL] [Abstract][Full Text] [Related]
9. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792 [TBL] [Abstract][Full Text] [Related]
10. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983 [TBL] [Abstract][Full Text] [Related]
11. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110 [TBL] [Abstract][Full Text] [Related]
12. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754 [TBL] [Abstract][Full Text] [Related]
13. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer. Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423 [TBL] [Abstract][Full Text] [Related]
14. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989 [TBL] [Abstract][Full Text] [Related]
16. Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories. Rosenthal ET; Bernhisel R; Brown K; Kidd J; Manley S Cancer Genet; 2017 Dec; 218-219():58-68. PubMed ID: 29153097 [TBL] [Abstract][Full Text] [Related]
17. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934 [TBL] [Abstract][Full Text] [Related]
18. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748 [TBL] [Abstract][Full Text] [Related]
19. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J; Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971 [TBL] [Abstract][Full Text] [Related]
20. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]